Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

Testosterone recovery was associated with improved OS in patients with high-risk prostate cancer treated with ADT and radiotherapy.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Artificial intelligence systems require consistent monitoring and staffing to put in place and to keep them working well.

The U.S. Senate voted largely along party lines to confirm Robert F. Kennedy Jr. to run the Department of Health and Human Services (HHS).

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.

Health Reform Will Provide Cancer Screening Services to Millions of Newly-Insured Women - but National Low-Income Screening Program Still 'Essential' ...

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.